Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions.

Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases.

Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT.

A phase I trial of Proton stereotactic body radiation therapy for liver metastases.

Background: A phase I trial to determine the maximum tolerated dose (MTD) of Proton stereotactic body radiation therapy (SBRT) for liver metastases in anticipation of a subsequent phase II study.

Methods: An institutional IRB approved phase I clinical trial was conducted. Eligible patients had 1-3 liver metastases measuring less than 5 cm, and no metastases location within 2 cm of the GI tract.